Eli Lilly and Company: Sarcoma trials
The registry lists 17 Sarcoma studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 15 have results posted.
Phase 1 11Phase 2 9Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial SarcomaTerminatedNCT04145700Phase 1/2Results posted
- CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell TumorCompletedNCT04145349Phase 1/2Results posted
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
- A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT03283696Phase 1Results posted
- A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT03126591Phase 1Results posted
- A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT02784795Phase 1Results posted
- A Study of Olaratumab (LY3012207) in Participants With Soft Tissue SarcomaCompletedNCT02783599Phase 1Results posted
- A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue SarcomaCompletedNCT02659020Phase 1/2Results posted
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT02451943Phase 3Results posted
- A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue SarcomaCompletedNCT02326025Phase 1Results posted
- A Study of Olaratumab in Soft Tissue SarcomaCompletedNCT01185964Phase 1/2Results posted
- Study in Advanced Solid TumorsCompletedNCT01099358Phase 2Results posted
- A Study in Advanced Solid TumorsCompletedNCT01063075Phase 2Results posted
- A Five-Tier, Open-Label Study of IMC-A12 in Advanced SarcomaCompletedNCT00668148Phase 2Results posted
- A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue SarcomaCompletedNCT00490451Phase 2Results posted
- FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
- Olaratumab (LY3012207) Patient Access for Soft Tissue SarcomaApproved for marketingNCT03994627